
European Journal of Medicinal Chemistry p. 789 - 797 (1998)
Update date:2022-07-29
Topics:
Dal Piaz, Vittorio
Giovannoni, Maria Paola
Castellana, Carla
Palacios, Jose Maria
Beleta, Jorge
Domenech, Teresa
Segarra, Victor
A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compounds are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theoretical calculations, performed on representative compounds, demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compounds. This finding could explain the different pharmacological profile of the title compounds with respect to the analogs reported in the literature.
View Morewebsite:https://en.yan-xi.com/
Contact:+86 17531190177--
Address:Zhang zhe, guangzong county, xingtai city, hebei province
Chemsigma International Co.,Ltd.
website:http://www.chemsigma.com
Contact:86-025-58748998
Address:Rm.705, 15th Building,Rd.Xinke II
Nanjing Chemzam Pharmtech Co., Ltd.
Contact:+86-25-86462165,+86-13915979898
Address:C5-1,6 Maiyue Road,Maigaoqiao,Nanjing,Jiangsu,China
website:http://www.truewingroup.com
Contact:86-311-66699812
Address:NO.600 ZHONGSHAN EAST ROAD SHIJIAZHUANG
Shandong Xinke Petrochemical Co., Ltd.
Contact:+86-546-7277016
Address:Gudao Industrial Park, Hekou District, Dongying, Shandong Province, China
Doi:10.1021/ja00149a011
(1995)Doi:10.1016/j.tetlet.2014.03.004
(2014)Doi:10.1055/s-1994-25545
(1994)Doi:10.1016/j.tet.2014.03.037
(2014)Doi:10.1039/c4cc00857j
(2014)Doi:10.1016/j.molcata.2014.01.005
(2014)